ライフサイエンスコーパス: SQV

1 SQV shows slightly improved polar interactions with PR(L

2 SQV-1 and SQV-7 are both expressed in the vulva and in o

3 SQV-1 localizes to punctate cytoplasmic compartments and

4 SQV-3 is similar to a family of glycosyltransferases tha

5 SQV-4 is expressed in the vulva and in oocytes, among ma

6 SQV-7 did not transport CMP-sialic acid, GDP-fucose, UDP

7 SQV-7 is able to transport UDP-Gal in vivo, as shown by

8 SQV-7 is similar to members of a family of nucleotide-su

9 One model is therefore that SQV-8 uses a SQV-3 product as a substrate.

10 SQV-1 and SQV-7 are both expressed in the vulva and in oocytes, wh

11 We conclude that C. elegans SQV-6 and SQV-2 likely act in concert with other SQV proteins to c

12 ich reduced the area of contact with APV and SQV; (ii) the compensating I84L mutation, which improved

13 and in oocytes, among many other cells, and SQV-4 levels are dramatically increased in a specific su

14 ctures of PR(L76V) in complexes with DRV and SQV were determined at resolutions of 1.45-1.46 A.

15 cing were done; 12 codons related to IDV and SQV resistance were analyzed.

16 , and 90 with in vitro resistance to IDV and SQV.

17 by 6 muM LPV while preserving inhibition by SQV and DRV.

18 We conclude that C. elegans SQV-6 and SQV-2 likely act in concert with other SQV pro

19 ction of Saccharomyces cerevisiae expressing SQV-7 transported UDP-glucuronic acid, UDP-N-acetylgalac

20 derstanding the loss of protease binding for SQV in the quadruple mutant and gain in binding for APV,

21 uences and 50% inhibitory concentrations for SQV and IDV at baseline.

22 (I54V) and that of PR(I54M) were similar for SQV and DRV.

23 ir (IDV) in patients with extensive hard-gel SQV experience.

24 th baseline CD4 cell count, HIV-1 RNA level, SQV experience, and drug susceptibility.

25 Using a combination of in vitro analysis of SQV enzymatic activities, sqv(+)-mediated rescue of vert

26 oduced steric repulsion with the P3 group of SQV.

27 6 and SQV-2 likely act in concert with other SQV proteins to catalyze the stepwise formation of the p

28 The predicted SQV-8 protein is similar in sequence to two mammalian be

29 A recombinant SQV-2 fusion protein had galactosyltransferase II activi

30 e of inhibitors darunavir (DRV), saquinavir (SQV), and lopinavir (LPV), relative to that of PR.

31 pen-label trial of a switch from saquinavir (SQV) hard capsules (SQVhc) to indinavir (IDV) or saquina

32 rial comparing 2 formulations of saquinavir (SQV) to indinavir (IDV) in patients with extensive hard-

33 of increasing concentrations of saquinavir (SQV), gave rise to a new variant containing M46I, G48V,

34 th I54M mutation) complexed with saquinavir (SQV) as well as PR(G48V) (PR with G48V mutation), PR(I54

35 We propose that SQV-7 translocates multiple nucleotide sugars into the G

36 One model is therefore that SQV-8 uses a SQV-3 product as a substrate.

37 lethality phenocopies RNAi depletion of the SQV-5 chondroitin synthase, suggesting that chondroitin

38 We cloned sqv-1 and showed that the SQV-1 protein is a type II transmembrane protein that fu

39 P-glucose dehydrogenases and showed that the SQV-4 protein specifically catalyzes the conversion of U

40 lasmic compartments and colocalizes with the SQV-7 nucleotide-sugar transporter, which probably acts

41 Among these, SQV-7, SRF-3, and CO3H5.2 exhibit partially overlapping

42 of G48V and I50V with clinical resistance to SQV and DRV, respectively.

43 a resulting phenotype that was resistant to SQV and, unexpectedly, resensitized to APV.

44 (G48V) was about twofold less susceptible to SQV than to DRV, whereas the opposite was observed for P

45 one previously demonstrated for transporter SQV-7, which shares a lower amino acid sequence identity

46 t unlike most nucleotide sugar transporters, SQV-7 can transport multiple distinct nucleotide sugars.